Figure 3.
Figure 3. Clinical presentations. The injected lesion (A) and a representative noninjected plaque (C) of patient 1 before (A,C) and after (B,D) treatment with intratumoral injection of measles vaccine virus preceded by subcutaneous IFN-α application. (E) The first injected plaque lesion of patient 2 before therapy, (F) after 6 days presenting edematous swelling and inflammation, (G) after 12 days and (H) clearing after 28 days. Thereafter, a tumor lesion was treated (I, overview) and (J, detail), again resulting in regression (K, overview; L, detail). The tumor lesions showed reduction in size and thickness after therapy. Images were acquired with a Leica RG camera (Leica, Jena, Germany).

Clinical presentations. The injected lesion (A) and a representative noninjected plaque (C) of patient 1 before (A,C) and after (B,D) treatment with intratumoral injection of measles vaccine virus preceded by subcutaneous IFN-α application. (E) The first injected plaque lesion of patient 2 before therapy, (F) after 6 days presenting edematous swelling and inflammation, (G) after 12 days and (H) clearing after 28 days. Thereafter, a tumor lesion was treated (I, overview) and (J, detail), again resulting in regression (K, overview; L, detail). The tumor lesions showed reduction in size and thickness after therapy. Images were acquired with a Leica RG camera (Leica, Jena, Germany).

Close Modal

or Create an Account

Close Modal
Close Modal